# Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Canonical URL: https://biopharmsignal.com/news/FULC/fulcrum-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c--af9b71b6
Ticker: FULC
Company: Fulcrum Therapeutics
Source: Fulcrum Therapeutics
Published: 2026-05-08 20:30 EST
## Summary

Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on...

## Article Body
Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to two new employees. Fulcrum granted stock options to purchase shares of the company’s common stock pursuant to the company’s 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employees entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4).

Fulcrum granted the new employees 55,500 options to purchase shares of the company’s common stock at an exercise price of $7.02 per share, the closing price per share of Fulcrum’s common stock as reported on the grant effective date, May 4, 2026. The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee’s start date and an additional 6.25% of the shares vesting in equal quarterly installments over the twelve successive quarters following the first anniversary, subject to the applicable employee’s continued service with the company through the applicable vesting dates.

About Fulcrum Therapeutics

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules that improve the lives of people with rare hematological disorders. The company’s lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin (HbF) for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of genetically defined diseases. For more information, visit www.fulcrumtx.com and follow us on X (@FulcrumTx) and LinkedIn.

Contact:

Kevin Gardner LifeSci Advisors, LLC kgardner@lifesciadvisors.com 617-283-2856
## Recent Company News
- 2026-06-01 20:05 EST — [Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review](https://biopharmsignal.com/news/FULC/fulcrum-therapeutics-announces-discontinuation-of-pociredir-program-in-sickle-ce-a4687a0d) — Source: Fulcrum Therapeutics
- 2026-05-08 20:30 EST — [Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/FULC/fulcrum-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c--af9b71b6) — Source: Fulcrum Therapeutics
- 2026-04-27 11:00 EST — [Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026](https://biopharmsignal.com/news/FULC/fulcrum-therapeutics-announces-recent-business-highlights-and-financial-results--b3f1692d) — Source: Fulcrum Therapeutics
- 2026-04-27 10:55 EST — [Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors](https://biopharmsignal.com/news/FULC/fulcrum-therapeutics-appoints-josh-lehrer-to-its-board-of-directors-6c29e5a6) — Source: Fulcrum Therapeutics
- 2026-04-20 12:00 EST — [Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ET](https://biopharmsignal.com/news/FULC/fulcrum-therapeutics-to-host-first-quarter-2026-financial-results-conference-cal-42a5e6f1) — Source: Fulcrum Therapeutics
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)